
Fear porn…


Pandemic maps are all the rage, these days, but the latest one from the Electronic Frontier Foundation (EFF) is a little different; instead of viral hotspots, it displays a plague of official snoopiness, arranged by location and sortable by technology. While it documents intrusions that predate the current crisis, the Atlas of Surveillance is all too relevant to the age of coronavirus. Concerns about curtailing contagion help to normalize detailed scrutiny of people’s lives and drive us toward a pervasive surveillance state.
“The Atlas of Surveillance database, containing several thousand data points on over 3,000 city and local police departments and sheriffs’ offices nationwide, allows citizens, journalists, and academics to review details about the technologies police are deploying, and provides a resource to check what devices and systems have been purchased locally,” EFF announced on July 13.
Users can click on the map to see what surveillance technologies are used in specified localities. If you want to see what’s going on in your area, the map is searchable by the name of a city, county, or state. The map can also be filtered according to technologies such as body-worn cameras, drones, and automated license plate readers.



In the months prior to the most ferocious stock market crash in history and the eruption of the biggest public health crisis of our generation, we witnessed the biggest exodus of corporate CEOs that we have ever seen. And as you will see below, corporate insiders also sold off billions of dollars worth of shares in their own companies just before the stock market imploded. In life, timing can be everything, and sometimes people simply get lucky. But it does seem odd that so many among the corporate elite would be so exceedingly “lucky” all at the same time. In this article I am not claiming to know the motivations of any of these individuals, but I am pointing out certain patterns that I believe are worth investigating.


Ahighly anticipated clinical trial for a potential COVID-19 vaccine managed in part by the American drug company Moderna has resulted is some adverse effects in more than half of the trial’s participants, with one test group reporting “severe” symptoms.
The trial, which is also being sponsored by the National Institute of Allergy and Infectious Diseases, administered the vaccine “as a 0.5-ml injection in the deltoid muscle” in two shots spaced about one month apart. Two separate groups received 25-microgram and 100-microgram doses, respectively. A third group with a 250-microgram dose was subsequently added.
The vaccine “induced anti–SARS-CoV-2 immune responses in all participants,” the research team reported Tuesday in the New England Journal of Medicine. Researchers said that “no trial-limiting safety concerns were identified.” Yet a majority of participants still reported at least one side effect.
Sen. Dianne Feinstein (D-Calif.) called on the Senate on Thursday to support an amendment to the next coronavirus relief bill that would bar states that do not implement mask mandates from receiving stimulus funding.
In a statement from the senator’s office, Feinstein announced her intention to introduce the amendment and stated that it was time for Congress to step in and force states to implement such mandates to stop the virus from spreading.
“Wearing masks in public should be mandatory. Period. [Senate Majority] Leader [Mitch] McConnell [R-Ky.] said the Senate will take up the next coronavirus economic relief bill later this month. At that time, I intend to offer an amendment to prohibit sending funds to states that haven’t adopted a statewide mask requirement,” said Feinstein, a member of the Senate Subcommittee on Agriculture, Rural Development, Food and Drug Administration.
“My hope has been that other governors would show the leadership to institute their own mask mandates, but so far that hasn’t happened. It’s time for Congress to step in. This is a matter of life or death, and partisan politics shouldn’t play a role,” she continued.
You must be logged in to post a comment.